Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGDS | O60760 | 1/20 | 0.55 |
| ▸ | TTBK1 | Q5TCY1 | 2/20 | 0.55 |
| ▸ | TTBK2 | Q6IQ55 | 2/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29853404 | 0.81 | GALR3 (0.62) | TTBK1TTBK2 | |
| SCHEMBL6268307 | 0.81 | GALR3 (0.62) | TTBK1TTBK2 | |
| SCHEMBL31707176 | 0.80 | — | — | |
| SCHEMBL28346037 | 0.79 | TTBK1 (0.59) | HPGDSTTBK1TTBK2 | |
| SCHEMBL12709725 | 0.79 | TTBK1 (0.59) | HPGDSTTBK1TTBK2 | |
| SCHEMBL31707056 | 0.79 | HPGDS (0.46) | HPGDS | |
| SCHEMBL1819928 | 0.78 | TTBK1 (0.52) | HPGDSTTBK1TTBK2 | |
| Hydrochloric Acid SCHEMBL29754738 | 0.78 | TTBK1 (0.57) | HPGDSTTBK1TTBK2 | |
| SCHEMBL25069022 | 0.78 | TTBK1 (0.56) | HPGDSTTBK1TTBK2 | |
| SCHEMBL3165812 | 0.77 | TTBK1 (0.61) | HPGDSTTBK1TTBK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230055961-A1 | PENTAFLUOROBENZENESULFONAMIDE DERIVATIVES AND USES THEREOF | DUNAD THERAPEUTICS LTD. (GB) | 2023-02-23 | — | — | US | disclosed |
| US-10421761-B2 | Compounds for kinase modulation, and indications therefor | PLEXXIKON INC. (US) | 2019-09-24 | — | — | US | disclosed |
| US-20180099975-A1 | COMPOUNDS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. | 2018-04-12 | — | — | US | disclosed |
| US-9873700-B2 | Compounds for kinase modulation, and indications therefor | PLEXXIKON INC. (US) | 2018-01-23 | — | — | US | disclosed |
| US-9617267-B2 | Compounds and methods for kinase modulation, and indications therefor | PLEXXIKON INC. (US) | 2017-04-11 | — | — | US | disclosed |
| US-9617267-B2 | Compounds and methods for kinase modulation, and indications therefor | PLEXXIKON INC. (US) | 2017-04-11 | — | — | US | disclosed |
| US-9617267-B2 | Compounds and methods for kinase modulation, and indications therefor | PLEXXIKON INC. (US) | 2017-04-11 | — | — | US | disclosed |
| EP-2501236-B1 | N-[2-fluoro-3-(4-amino-7H-pyrrolo[2,3-d]pyrimidine-5-carbonyl)-phenyl]-4-benzenesulfonamide derivatives as Raf protein kinase modulators for the treatment of cancer | PLEXXIKON INC (US) | 2017-03-29 | — | — | EP | disclosed |
| EP-2501236-B1 | N-[2-fluoro-3-(4-amino-7H-pyrrolo[2,3-d]pyrimidine-5-carbonyl)-phenyl]-4-benzenesulfonamide derivatives as Raf protein kinase modulators for the treatment of cancer | PLEXXIKON INC (US) | 2017-03-29 | — | — | EP | disclosed |
| CN-105906631-A | Compounds and methods for kinase modulation, and indications therefor | 普莱希科公司 | 2016-08-31 | — | — | CN | disclosed |
| US-8673928-B2 | Compounds and methods for kinase modulation, and indications therefor | PLEXXIKON INC. (US) | 2014-03-18 | — | — | US | disclosed |
| US-8673928-B2 | Compounds and methods for kinase modulation, and indications therefor | PLEXXIKON INC. (US) | 2014-03-18 | — | — | US | disclosed |
| US-8673928-B2 | Compounds and methods for kinase modulation, and indications therefor | PLEXXIKON INC. (US) | 2014-03-18 | — | — | US | disclosed |
| CN-102740698-A | Compounds and methods for kinase modulation and indications therefor | PLEXXIKON INC | 2012-10-17 | — | — | CN | disclosed |
| EP-2501236-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | Plexxikon, Inc. (US) | 2012-09-26 | — | — | EP | disclosed |
| US-20110152258-A1 | Compounds and Methods for Kinase Modulation, and Indications Therefor | PLEXXIKON INC. | 2011-06-23 | — | — | US | disclosed |
| US-20110152258-A1 | Compounds and Methods for Kinase Modulation, and Indications Therefor | PLEXXIKON INC. | 2011-06-23 | — | — | US | disclosed |
| US-20110152258-A1 | Compounds and Methods for Kinase Modulation, and Indications Therefor | PLEXXIKON INC. | 2011-06-23 | — | — | US | disclosed |
| WO-2011063159-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON, INC. (US) | 2011-05-26 | — | — | WO | disclosed |
| WO-2011063159-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON, INC. (US) | 2011-05-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110152258-A1 | Compounds and Methods for Kinase Modulation, and Indications Therefor | BRAF, KRAS, RAF1 | HPGDS 566/4885TTBK1 770/4885TTBK2 1070/4885 |
| US-20230055961-A1 | PENTAFLUOROBENZENESULFONAMIDE DERIVATIVES AND USES THEREOF | FURIN, PFAS, CFTR | HPGDS 396/4885TTBK1 3603/4885TTBK2 2919/4885 |
| US-10421761-B2 | Compounds for kinase modulation, and indications therefor | MAP3K20, MAP3K13, MAP3K8 | HPGDS 771/4885TTBK1 314/4885TTBK2 288/4885 |
| US-20180099975-A1 | COMPOUNDS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | MAP3K20, MAP3K13, MAP3K8 | HPGDS 771/4885TTBK1 314/4885TTBK2 288/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.